Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy
about
AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Vacuum-Sealing as a Treatment Option for Severe Anthracycline Extravasation in a Breast Cancer Patient.Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovaryDexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in PigsAnthracycline extravasation injuries: management with dexrazoxane.Management of anthracycline extravasation into the pleural spaceAll-trans retinoic acid protects against doxorubicin-induced cardiotoxicity by activating the ERK2 signalling pathwayDexrazoxane efficacy for anthracycline extravasation: use in UK clinical practice.Treatment of anthracycline extravasations using dexrazoxane.Dexrazoxane: a management option for anthracycline extravasations.Extravasation injuries: a review.Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia.Anthraquinones As Pharmacological Tools and Drugs.Diethyl Blechnic, a Novel Natural Product Isolated from Bunge, Inhibits Doxorubicin-Induced Apoptosis by Inhibiting ROS and Activating JNK1/2
P2860
Q30318240-05A5F635-5204-4412-9C0C-3BB7390A784CQ34096302-DAAD8329-49B9-4CC3-A7A4-ED9AC7F74C74Q35201332-97C28AA8-DA60-48B6-AA5A-92B274F03786Q36230443-A01E333A-9305-4547-9EC8-41CB8330E323Q37230281-BFA19080-4DAE-4509-A255-602DE357586EQ37302166-EE2B589D-2622-4DC7-BA07-D701907ECA5EQ37686126-B6D0A26F-4BCA-44AB-8353-7ED72F5ED119Q38081464-39798CD2-C140-44CD-A373-2BEFB895D05FQ38129316-893D630E-39D2-4C50-B988-00F0ED410193Q38143321-0FE1C0C0-F9AE-4B27-B06C-CEEC5D04D0C3Q38176727-7E51EA47-5935-4549-9519-6ACC1447B2E6Q38809957-C6C63CBB-AB3A-45C8-99D9-1CC81552B69AQ38816745-1B36FD95-DCB8-415E-855C-7E20A663C8D0Q57552177-930CD298-B708-481F-B10E-43458C01F580
P2860
Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Dexrazoxane (Totect): FDA revi ...... ous anthracycline chemotherapy
@ast
Dexrazoxane (Totect): FDA revi ...... ous anthracycline chemotherapy
@en
Dexrazoxane (Totect): FDA revi ...... ous anthracycline chemotherapy
@nl
type
label
Dexrazoxane (Totect): FDA revi ...... ous anthracycline chemotherapy
@ast
Dexrazoxane (Totect): FDA revi ...... ous anthracycline chemotherapy
@en
Dexrazoxane (Totect): FDA revi ...... ous anthracycline chemotherapy
@nl
prefLabel
Dexrazoxane (Totect): FDA revi ...... ous anthracycline chemotherapy
@ast
Dexrazoxane (Totect): FDA revi ...... ous anthracycline chemotherapy
@en
Dexrazoxane (Totect): FDA revi ...... ous anthracycline chemotherapy
@nl
P2093
P3181
P1433
P1476
Dexrazoxane (Totect): FDA revi ...... ous anthracycline chemotherapy
@en
P2093
Ramzi Dagher
Richard Pazdur
Robert C Kane
Robert Justice
W David McGuinn
P304
P3181
P356
10.1634/THEONCOLOGIST.2007-0247
P407
P577
2008-04-01T00:00:00Z